Results 41 to 50 of about 54,096 (328)

Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study [PDF]

, 2019
Splenomegaly is one of the major clinical manifestations of primary myelofibrosis and is common also in other chronic Philadelphia-negative myeloproliferative neoplasms, causing symptoms and signs and affecting quality of life of patients diagnosed with ...
Accurso V., Casimiro P., Contrino A. D., Di Piazza F., Perez A., Raso S., Russo A., Santoro M., Siragusa S.   +8 more
core   +1 more source

Platelets as mediators of Thromboinflammation in chronic Myeloproliferative Neoplasms [PDF]

, 2019
Chronic myeloproliferative neoplasms (MPN) are stem cell disorders driven by mutations in JAK2, CALR, or MPL genes and characterized by myeloid proliferation and increased blood cell counts.
Heller, Paula Graciela, Marin Oyarzún, Cecilia Paola   +1 more
core   +1 more source

Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase

Haematologica, 2010
Primary myelofibrosis shows histological and pathogenetic overlap with essential thrombocythemia and polycythemia vera. Several diagnostic classifications have been proposed for primary myelofibrosis, although little is known about their clinical utility.
Philip A. Beer, Peter J. Campbell, Anthony R. Green   +2 more
doaj   +1 more source

Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.

Blood Advances, 2021
We aimed to study the prognostic impact of the mutational landscape in primary and secondary myelofibrosis. The study included 479 patients with myelofibrosis recruited from 24 French Intergroup of Myeloproliferative Neoplasms (FIM) centers.
D. Luque Paz, J. Riou, E. Verger, B. Cassinat, A. Chauveau, J. Ianotto, B. Dupriez, F. Boyer, Maxime Renard, Olivier Mansier, A. Murati, J. Rey, G. Étienne, V. Mansat-De Mas, S. Tavitian, O. Nibourel, S. Girault, Y. Le Bris, F. Girodon, D. Ranta, J. Chomel, P. Cony-Makhoul, P. Sujobert, M. Robles, R. Ben Abdelali, O. Kosmider, L. Cottin, L. Roy, I. Sloma, Fabienne Vacheret, M. Wémeau, P. Mossuz, B. Slama, Vincent Cussac, G. Denis, A. Walter-Petrich, B. Burroni, Nathalie Jézéquel, S. Giraudier, E. Lippert, G. Socié, J. Kiladjian, V. Ugo   +42 more
semanticscholar   +1 more source

Osteochondrosis lesions of the lateral trochlear ridge of the distal femur in four ponies [PDF]

, 2011
Lesions of the lateral trochlear ridge (LTR) of the distal femur were investigated in four pony or pony cross horses. The animals were all geldings and were six to 15 months of age.
Henson, F.M.D., Jeffcott, L.B., Platt, D., Voute, L.C.   +3 more
core   +1 more source

Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis

Haematologica, 2015
Primary myelofibrosis is characterized by clonal myeloproliferation, dysmegakaryopoiesis, extramedullary hematopoiesis associated with myelofibrosis and altered stroma in the bone marrow and spleen.
Christophe Desterke, Christophe Martinaud, Bernadette Guerton, Lisa Pieri, Costanza Bogani, Denis Clay, Frederic Torossian, Jean-Jacques Lataillade, Hans C. Hasselbach, Heinz Gisslinger, Jean-Loup Demory, Brigitte Dupriez, Claude Boucheix, Eric Rubinstein, Sophie Amsellem, Alessandro M. Vannucchi, Marie-Caroline Le Bousse-Kerdilès   +16 more
doaj   +1 more source

Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT

Leukemia, 2021
JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined.
N. Kröger, Giulia Sbianchi, Tiarlan Sirait, C. Wolschke, D. Beelen, J. Passweg, M. Robin, R. Vrhovac, G. Helbig, K. Sockel, E. Conneally, M. Rubio, Y. Beguin, J. Finke, P. Bernasconi, E. Morozova, J. Clausen, P. A. von dem Borne, N. Schaap, W. Schroyens, F. Patriarca, N. Di Renzo, Z. Yeğin, P. Hayden, D. Mclornan, I. Yakoub-Agha   +25 more
semanticscholar   +1 more source

Splanchnic vein thrombosis in myeloproliferative neoplasms: Pathophysiology and molecular mechanisms of disease [PDF]

, 2016
Myeloproliferative neoplasms (MPNs) are the most common underlying prothrombotic disorder found in patients with splanchnic vein thrombosis (SVT). Clinical risk factors for MPN-associated SVTs include younger age, female sex, concomitant hypercoagulable ...
How, Joan, Oh, Stephen T, Zhou, Amy
core   +2 more sources

Advances in myelofibrosis: a clinical case approach

Haematologica, 2013
Primary myelofibrosis is a member of the myeloproliferative neoplasms, a diverse group of bone marrow malignancies. Symptoms of myelofibrosis, particularly those associated with splenomegaly (abdominal distention and pain, early satiety, dyspnea, and ...
John O. Mascarenhas, Attilio Orazi, Kapil N. Bhalla, Richard E. Champlin, Claire Harrison, Ronald Hoffman   +5 more
doaj   +1 more source

Transcriptional profiling of whole blood identifies a unique 5-gene signature for myelofibrosis and imminent myelofibrosis transformation. [PDF]

PLoS ONE, 2014
Identifying a distinct gene signature for myelofibrosis may yield novel information of the genes, which are responsible for progression of essential thrombocythemia and polycythemia vera towards myelofibrosis.
Hans Carl Hasselbalch, Vibe Skov, Thomas Stauffer Larsen, Mads Thomassen, Caroline Hasselbalch Riley, Morten K Jensen, Ole Weis Bjerrum, Torben A Kruse   +7 more
doaj   +1 more source